Corline Biomedical Q3 (Review) - Sales growth incoming

Redeye provides an update following Corline’s Q3 2025 report. Sales came in slightly below expectations; however, during the early stages of the Globe launch, some quarterly fluctuations are to be expected, and we see no cause for concern. Based on the report, we have made minor revisions to our estimates, resulting in an updated fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/